These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18806838)

  • 1. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma.
    Bachanova V; Brunstein CG; Burns LJ; Miller JS; Luo X; Defor T; Young JA; Weisdorf DJ; Tomblyn M
    Bone Marrow Transplant; 2009 Feb; 43(3):237-44. PubMed ID: 18806838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation.
    Meijer E; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK; Verdonck LF
    Transpl Infect Dis; 2004 Dec; 6(4):171-8. PubMed ID: 15762935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.
    Nachbaur D; Larcher C; Kircher B; Eibl G; Nussbaumer W; Gunsilius E; Haun M; Grünewald K; Gastl G
    Ann Hematol; 2003 Oct; 82(10):621-7. PubMed ID: 12920570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC
    Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention.
    Safdar A; Rodriguez GH; Mihu CN; Mora-Ramos L; Mulanovich V; Chemaly RF; Champlin RE; Khouri I
    Bone Marrow Transplant; 2010 Feb; 45(2):339-47. PubMed ID: 19561648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation.
    Martino R; Caballero MD; Canals C; San Miguel J; Sierra J; Rovira M; Solano C; Bargay J; Pérez-Simon J; León A; Sarrá J; Brunet S; de la Cámara R;
    Bone Marrow Transplant; 2001 Aug; 28(4):341-7. PubMed ID: 11571505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia.
    Cordonnier C; Maury S; Esperou H; Pautas C; Beaune J; Rodet M; Lagrange JL; Rouard H; Beaumont JL; Bassompierre F; Glückman E; Kuentz M; Durand-Zaleski I
    Bone Marrow Transplant; 2005 Oct; 36(7):649-54. PubMed ID: 16044135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable incidence and severity of cytomegalovirus infections following T cell-depleted allogeneic stem cell transplantation preceded by reduced intensity or myeloablative conditioning.
    Kalpoe JS; van der Heiden PL; Vaessen N; Claas EC; Barge RM; Kroes AC
    Bone Marrow Transplant; 2007 Jul; 40(2):137-43. PubMed ID: 17530007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
    Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
    Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning.
    Yoshihara S; Tateishi U; Ando T; Kunitoh H; Suyama H; Onishi Y; Tanosaki R; Mineishi S
    Bone Marrow Transplant; 2005 Jun; 35(12):1195-200. PubMed ID: 15852024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
    Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
    Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
    Narreddy S; Mellon-Reppen S; Abidi MH; Klein JL; Peres E; Heilbrun LK; Smith D; Alangaden G; Chandrasekar PH
    Transpl Infect Dis; 2007 Mar; 9(1):3-10. PubMed ID: 17313464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.
    Frère P; Baron F; Bonnet C; Hafraoui K; Pereira M; Willems E; Fillet G; Beguin Y
    Bone Marrow Transplant; 2006 Feb; 37(4):411-8. PubMed ID: 16415900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Tomblyn M; Brunstein C; Burns LJ; Miller JS; MacMillan M; DeFor TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2008 May; 14(5):538-45. PubMed ID: 18410896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant.
    Shaw BE; Mufti GJ; Mackinnon S; Cavenagh JD; Pearce RM; Towlson KE; Apperley JF; Chakraverty R; Craddock CF; Kazmi MA; Littlewood TJ; Milligan DW; Pagliuca A; Thomson KJ; Marks DI; Russell NH
    Bone Marrow Transplant; 2008 Dec; 42(12):783-9. PubMed ID: 18724393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenoviral infections after transplantation of positive selected stem cells from haploidentical donors in children: an update.
    Feuchtinger T; Richard C; Pfeiffer M; Neuhäuser F; Lücke J; Handgretinger R; Greil J; Bader P; Klingebiel T; Schlegel PG; Jahn G; Niethammer D; Lang P
    Klin Padiatr; 2005; 217(6):339-44. PubMed ID: 16307420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients.
    Martín-Peña A; Aguilar-Guisado M; Espigado I; Parody R; Miguel Cisneros J
    Clin Transplant; 2011; 25(3):468-74. PubMed ID: 20482561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of nonmyeloablative conditioning regimens on the occurrence of pure red cell aplasia after ABO-incompatible allogeneic haematopoietic stem cell transplantation.
    Malfuson JV; Amor RB; Bonin P; Rodet M; Boccaccio C; Pautas C; Kuentz M; Cordonnier C; Noizat-Pirenne F; Maury S
    Vox Sang; 2007 Jan; 92(1):85-9. PubMed ID: 17181595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.